Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial Prof Sagar Lonial, MDa Send email to sloni01@emory.edu ∙ Prof Meletios A Dimopoulos, MDb,c ∙ Maria Gavriatopoulou, MDb ∙ Prof Kihyun Kim, MDd ∙ Prof Chang-Ki Min, MDe ∙ Albert Oriol, MDf ∙ et al.

Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial Prof Sagar Lonial, MDa Send email to sloni01@emory.edu ∙ Prof Meletios A Dimopoulos, MDb,c ∙ Maria Gavriatopoulou, MDb ∙ Prof Kihyun Kim, MDd ∙ Prof Chang-Ki Min, MDe ∙ Albert Oriol, MDf ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00450-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ims26&_hsenc=p2ANqtz--hzbEX0tUUh7eZZeRTeGq5sidbMN8haHsXcXt0bwOBrUsMk42dPY-eSMPHLiyE8mMxJPyqrv6Xd4GW6CSm8CJibJw9Qw&_hsmi=442274516&utm_source=hs_email